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Aim: To assess the effect of changing clinical practice on the costs and outcomes of percutaneous coronary
intervention (PCI) between 1998 and 2002.
Setting: Two tertiary interventional centres.
Patients: Consecutive patients undergoing PCI over a 12-month period between 1998 and 2002.
Design: Comparative observational study of costs and 12-month clinical outcomes of consecutive PCI
procedures in 1998 (n = 1047) and 2002 (n = 1346). Clinical data were recorded in the Scottish PCI register.
Repeat PCI, coronary artery bypass graft and mortality were obtained by record linkage. Costs of equipment
were calculated using a computerised bar-code system and standard National Health Service reference costs.
Results: Between 1998 and 2002, the use of bare metal stents increased from 44% to 81%, and the use of
glycoprotein IIB/IIIA inhibitors increased from 0% to 14% of cases. During this time, a significant reduction
was observed in repeat target-vessel PCI (from 8.4% to 5.1%, p = 0.001), any repeat PCI (from 11.7% to
9.2%, p = 0.05) and any repeat revascularisation (from 15.1% to 11.3%, p = 0.009) within 12 months.
Significantly higher cost per case in 2002 compared with 1998 (mean (standard deviation) £2311 (1158) v
£1785 (907), p,0.001) was mainly due to increased contribution from bed-day costs in 2002 (45.0%
(16.3%) v 26.2% (12.6%), p = 0.01) associated with non-elective cases spending significantly longer in
hospital (6.22 (4.3) v 4.6 (4.3) days, p = 0.01).
Conclusions: Greater use of stents and glycoprotein IIb/IIIa inhibitors between 1998 and 2002 has been
accompanied by a marked reduction in the need for repeat revascularisation. Longer duration of hospital stay
for non-elective cases is mainly responsible for increasing costs. Strategies to reduce the length of stay could
considerably reduce the costs of PCI.
P
ercutaneous coronary intervention (PCI) is now the most
commonly used form of coronary revascularisation in the
UK.1 2 Technological advances in equipment and adjuvant
drug treatments over the past 15 years, including stents,
glycoprotein IIb/IIIa inhibitors and clopidogrel, have improved
clinical outcomes,3–6 but potentially added to procedure-related
costs. The cost effectiveness of these advances has been
examined in the context of randomised trials, and in each case
has suggested that the additional costs are recouped by reduced
need for readmission to hospital, reduced need for repeat
revascularisation procedures, or both.7–10
When estimating costs and cost effectiveness of PCI in
clinical practice, there are several important factors to consider.
Firstly, although new technologies, such as stents, are initially
expensive, the cost has fallen with time as their use increases
and competition among manufacturers has increased.
Secondly, stents are only one of the main cost drivers of PCI.
Angioplasty balloons, bed-days and adjuvant drug treatment
also contribute appreciably to procedural costs.11 Thirdly, it is
not known whether the net effect of multiple new interventions
is achieved in ‘‘real-world’’ clinical practice. ‘‘Real-world’’
patients tend to be older, have more comorbidity and are
generally more heterogeneous than those in randomised trials.
Therefore, there is a need to assess the costs and outcomes of
PCI with time and with changing technologies in the clinical
setting to which they are applied. This is increasingly important
as new systems of financial remuneration are introduced in the
UK12 and elsewhere in the world.13 14
In this study, we have compared detailed procedural costs of
PCI in unselected consecutive cases over a 12-month period in
1998 and 2002 at two interventional centres when there were
considerable changes in clinical practice.
METHODS
Patient recruitment
In all, 1047 and 1346 consecutive patients with a PCI procedure
in the two centres between February 1997 and May 1998, and
February 2001 and February 2002, respectively, were included
in the analysis. Data were recorded prospectively at each centre
in an Access database as part of the Scottish PCI register,
including clinical status of the procedure (non-elective or
elective), cardiovascular risk factors, severity of coronary
disease, left ventricular function, vessel diameter and number
of bare metal stents (BMS) deployed. Ethical approval for the
study was obtained from the appropriate research ethics
committees at both the centres involved.
Procedural costs
The first stage was to explore which elements of the cost of a
PCI were the most important so that these could be the focus of
further data collection. The use of BMS, balloons, wires, guides,
standard equipment, standard drugs, contrast and staff costs
were assessed in 100 consecutive cases in the year 2000. For
these cases, the items that acted as the main cost drivers were
found to be BMS, balloons and bed-days; the remaining items
made up only 10–20% of the total costs and were combined as a
fixed cost. Further data collection centred on these items, as
well as glycoprotein IIb/IIIa inhibitors, which came into use
after this time. These 100 cases were found to be representative
of the larger cohort studied for urgency, age, disease severity
and number of vessels treated.
Abbreviations: BMS, bare metal stents; CABG, coronary artery bypass
graft; PCI, percutaneous coronary intervention
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For each of the 1047 PCI procedures in 1998, cost per
procedure was calculated by using fixed costs (as defined
above) added to the three main cost drivers (bed-days, balloons
and BMS) for each case (appendix). Data on use of balloons
and BMS for each procedure were taken from the PCI register,
and time in hospital was taken from the individual patient’s
data recorded in the Scottish Morbidity Record 1 system,
multiplied by the reference cost for one day’s stay in a standard
medical ward (Scottish Health Service Costs.15
For the estimation of costs of PCI cases in 2002, detailed
information was collected prospectively on all 1346 consecutive
procedures and included the number of balloons, BMS,
duration of hospital stay, guide wires, guide catheters, non-
standard equipment and use of glycoprotein IIb/IIIa inhibitors
for each PCI procedure. A fixed quantity for the remaining cost
components (standard equipment, standard drugs and staff)
was added to obtain the total cost of each procedure
(appendix). Capital costs of equipment and buildings were
not included in the calculations.
Outcomes of PCI
Outcome data were collected via linkage of records in the PCI
register, with the Information and Statistics Division of the
Common Services Agency using data on deaths from the
Scottish Mortality Record 1 and General Registrar. Subsequent
events recorded included repeat PCI (K49 and K50.1) and
coronary artery bypass graft (CABG; K40–K46). Any PCI
procedure in the same arterial territory as the index PCI was
defined as a repeat target-vessel PCI. These data were obtained
from the PCI register. Dates of admission and discharge were
obtained from the Information and Statistics Division to allow
estimation of costs related to duration of hospital stay. Adverse
events in the cardiac laboratory included acute closure of a
major coronary vessel resulting in myocardial infarction
(creatine kinase twice the upper limit of normal), side branch
occlusion (resulting in myocardial infarction), urgent CABG,
cerebrovascular injury, haemorrhage requiring transfusion, and
vascular access complications. The success of the procedure was
defined by the operator at the end of each procedure.
Statistical methods
Data are presented as mean (standard deviation (SD)) and 95%
confidence intervals for the mean. The x2 test was used to
compare percentages between groups. Means between groups
were compared using analysis of variance or the t test.
RESULTS
Patient characteristics
Compared with 1998, patients treated in 2002 (table 1) were
older, had a higher body mass index, had more single vessel
disease, had significantly lower angina scores and were less
likely to have left ventricular dysfunction. There was a similar
number of patients with diabetes and hypertension, a lower
proportion of current smokers and a greater number with
previous myocardial infarction in 2002. The proportion of cases
defined as non-elective in 2002 was significantly greater than in
1998 (43% v 31%, p,0.001).
Procedure-related differences between 1998 and 2002
Between 1998 and 2002 the use of BMS and also the use of
glycoprotein IIb/IIIa inhibitors increased significantly (table 1).
The maximum diameter of the treated vessel was significantly
smaller in 2002. There was a higher rate of operator-defined
procedural success in 2002 and a small but significant increase
in in-laboratory adverse event rates. Adverse events reported in
2002 were due to myocardial infarction (19), cerebrovascular
injury (4), femoral access site complications, including
haemorrhage (10), emergency CABG (1) and death (1). The
length of stay reduced slightly for elective procedures and
increased considerably for non-elective cases. The mean (SD)
length of stay for patients with an adverse in-laboratory event
in 2002 was slightly shorter, although non-significant, com-
pared with patients with no adverse event (3.9 (3.8) v 4.5 (3.6),
respectively, p = 0.37).
Costs
Overall, there was a 30% increase in the average cost of a PCI
procedure between 1998 and 2002 (table 2); this is equivalent
to an annual inflation rate in the cost of the procedure of just
over 6% at a time when the rate for the rest of the UK economy
was running at about a half of that level. This change was most
marked in non-elective cases, where a 47% increase was
observed, an inflation rate of almost 10%. The main contribu-
tion to the increase in costs was bed-days (duration of hospital
stay), with other equipment costs (BMS and balloons)
contributing proportionally less in 2002 than in 1998.
Clinical outcomes
Comparing outcomes in 1998 with 2002 (table 3), there was a
significant reduction in repeat target-vessel PCI (from 8.4% to
5.1%, p = 0.001) and a significant reduction in repeat PCI to any
vessel (from 11.7% to 9.2%, p = 0.05) in the 12 months after the
index PCI. There was no significant difference in the number of
patients undergoing CABG, but overall, the total number of
repeat revascularisations was significantly reduced (from 15.1%
to 11.3%, p = 0.009) within 12 months of the first PCI in 2002
compared with 1998.
DISCUSSION
In this study, we observed that, between 1998 and 2002, in
unselected consecutive patients undergoing PCI, greater use of
BMS and glycoprotein IIB/IIIA inhibitors was associated with a
similar 1-year mortality and a reduced need for repeat
revascularisation within 12 months. These changes occurred
despite a more adverse risk profile of patients treated in 2002, in
relation to age, smaller vessel diameter, more previous
myocardial infarction and a greater number of non-elective
cases. Over the same time period, we observed a small increase
in in-laboratory adverse event rates and a greater in-laboratory
lesion success rate. These findings are in keeping with other
data from PCI registry, suggesting that interventionists are
increasingly treating older patients with more complex disease
in smaller coronary arteries while improving lesion-related
results, with no marked change in mortality.16
Between 1998 and 2002, we observed a 30% increase in the
mean cost of a PCI procedure. The reasons for this increase in
cost are complex and not simply due to greater use of BMS and
adjuvant drugs. Stents contributed proportionally less to the
mean cost of a PCI in 2002 compared with 1998. There was a
marked difference in the change in costs between elective and
non-elective procedures. The increase in mean cost for elective
procedures was 10% over 5 years, which is broadly in line with
inflation, whereas the greatest increase in costs was observed
for non-elective procedures. This was largely due to a
considerably longer average duration of stay for non-elective
cases in 2002. The net change in cost of interventional
procedures between 1998 and 2002 is therefore a complex
sum of greater use of less expensive equipment, greater use of
glycoprotein IIb/IIIa inhibitors offset by longer duration of
hospital stay in an increasing proportion of non-elective
procedures.
The question remains—does this change in clinical practice,
resulting in greater cost, represent value for money? This is a
difficult question to answer, but can be discussed by examining
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data from this study. For elective procedures, the additional
cost per case was £174, which was close to that expected from
inflation over a 4–5-year period and therefore represents an
overall neutral effect on cost. Therefore, if we use the observed
reduction in repeat revascularisation procedures of 3% for PCI
and 1% for CABG (three PCI procedures and one CABG per 100
patients treated) in 2002 compared with 1998, this represents a
net cost saving of approximately £12 000 per 100 elective cases
treated. The same calculation for non-elective procedures
produces a net increase in cost of approximately £40 000 per
100 cases treated in 2002 compared with 1998. It is clear
therefore, that the cost effectiveness of BMS and glycoprotein
IIb/IIIa inhibitors is being diluted in clinical practice by the
effect of longer duration of hospital stay.
Increased length of stay may be partly related to increasing
complexity of cases and is probably not related to an increased
adverse event rate in 2002, as these patients had a similar
length of stay to those patients with no adverse event. Longer
Table 2 Costs of percutaneous coronary intervention, 1998 v 2002
1998 2002
Change (%) p Valuen Mean (SD) n Mean (SD)
Overall (cost, £) 1047 1785 (907) 1346 2311 (1158) +30 ,0.001
Elective (cost, £) 717 1694 (885) 727 1868 (782) +10 ,0.001
Non-elective (cost, £) 326 1989 (929) 540 2924 (1307) +47 ,0.001
Procedure cost (%)
Stents (BMS; %) 1047 27.9 (32.8) 1346 19.9 (13.2) 240 ,0.001
Balloons (%) 1047 22.4 (20.3) 1346 6.4 (6.0) 271 ,0.001
Bed-days (%) 1047 26.2 (12.6) 1346 45.0 (16.3) +72 ,0.001
GP IIb/IIIa (%) 1047 0 (0) 1346 3.4 (8.7) ,0.000
BMS, bare metal stents; GP, glycoprotein.
Table 1 Characteristics of patients in 1998 and 2002
Factor
1998 2002
p Valuen Mean (SD) or % n Mean (SD) or %
Age (years) 1047 59.4 (10.0) 1346 61.0 (10.2) ,0.001
Male (%) 1047 69 1299 67 0.39
BMI 988 27.2 (4.2) 704 28.3 (4.6) ,0.001
Number of diseased vessels (%) 1017 1263
1 44 53
2 32 30
3 24 17
Procedure status (%) 1043 1267 ,0.001
Elective 69 57
Non-elective 31 43
Angina score (%) 1007 996 ,0.001
0–1 3 29
2–3 60 30
4 37 40
Left ventricular dysfunction (%) 808 1256
Normal 59 77 ,0.001
Mild 27 15
Moderate 10 5
Severe 3 3
Smoking status (%) 1027 894
Non-smokers 31 61 ,0.001
Current smokers 23 9
Ex smokers 46 30
Diabetes (%) 1018 11 1131 11 0.8
Hypertension (%) 1021 35 994 33 0.46
Previous myocardial infarction (%) 1047 42 1157 37 0.013
Previous CABG (%) 1016 11 1224 11 0.64
Procedural success (%) 1047 92 1256 96 ,0.001
In-laboratory adverse events (%) 1047 1.1 1346 2.7 ,0.01
Any stents used (%) 1044 44 1346 81 ,0.001
Stents used per procedure (mean) 1044 0.84 (1.20) 1346 1.16 (0.86) ,0.001
Vessel diameter (mm) 1031 3.17 (0.53) 1206 3.05 (0.48) ,0.001
Any GP IIb/IIa used 1047 0 1346 14 ,0.001
Length of stay (days) 884 3.31(2.98) 1346 4.4(3.6) ,0.001
Elective 633 2.78(2.07) 727 2.72(2.1) 0.10
Non-elective 249 4.63(4.26) 540 6.22(4.3) ,0.001
BMI, body mass index; CABG, coronary artery bypass graft; GP, glycoprotein.
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duration of stay is more likely to be due to organisational issues
and the growing demand for inpatient angiography and
intervention, resulting in delays in transfer of patients from
district hospitals to the two interventional centres involved in
this study.17 It does suggest that a reduction in the length of
hospital stay could markedly reduce costs of non-elective PCI.
One possible mechanism that might improve this in our region
would be the allocation of specific ‘‘ring-fenced’’ beds in
interventional centres for patients requiring urgent angiogra-
phy, allowing faster and efficient transfer of patients from
district hospitals to interventional centres.18
Increased use of BMS from 44% in 1998 to 81% in 2002
observed in our registry would have been expected to result in a
relative risk reduction in repeat revascularisation by approxi-
mately 25%,4 which is very close to what we observed (15.1% to
11.3%). This suggests that the additional cost of BMS is being
recouped in terms of reduced need for repeat procedures, but
this is being diluted by the costs of additional bed-days.
Reducing the length of hospital stay is a key part of the current
strategy associated with payment by result.19
LIMITATIONS
There are limitations to this study that should be considered
when interpreting the findings. The outcome data used in our
analysis included hospital discharge coding in Scotland and
hence, although the numbers are likely to be small, a patient
admitted and treated elsewhere in the UK would not be
included. The costs and outcomes presented do not constitute a
cost-effectiveness analysis, but are simply an estimate of the
procedure-related costs of PCI and the crude outcomes in terms
of the need for repeat revascularisation. Some of the clinical
data are missing, but most data relating to costs and outcomes
were complete. Detailed information regarding the cause for
longer hospital stays in non-elective patients are not available,
and hence further studies are required to examine this.
CONCLUSIONS
Between 1998 and 2002, the costs of non-elective PCI
procedures increased much more than inflation mainly due to
an increase in the cost of bed-days associated with longer
duration of hospital stay. During the same time period, the cost
of elective PCI procedures increased in line with inflation.
Although this may be partly due to increasing complexity of
non-elective cases, clinical strategies that speed up transfer of
patients and shorten hospital stay of non-elective PCI proce-
dures could considerably improve its cost effectiveness.
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Retrograde coronary interventions of chronic total occlusions
A
43-year-old man presented with several
months of effort angina. Angiography
showed a totally occluded mid-portion
obstruction of the right coronary artery (RCA)
and very good collaterals from the left
coronary artery, filling retrogradely the distal
RCA (panel A). Multiple trials to cross the
mid-RCA through an anterograde approach
with various guide wires failed. Therefore, we
finished the procedure and planned the retro-
grade RCA intervention after 2 days. Both
coronary arteries were engaged by guiding
catheters, and various guide wires were tried
to pass the lesion through the collaterals
retrogradely, but it was very difficult to pass
the lesion (panel B). Finally, the guide wire
(Conquest pro ASAHI INTECC, Osaka, Japan)
passed the lesion with the support of a
microcatheter (Renegade Boston Scientific,
Natick, Massachusetts, USA). Then a 1.5–
15 mm size percutaneous transluminal coron-
ary angioplasty balloon (Ryujin, Terumo,
Japan) was inserted through the collaterals
via a retrograde guide wire and inflated to
10 atm (panel C). The second guide wire was
introduced antegradely and easily passed the
lesion. The lesion was successfully dilated
(panel D) and two long Cypher stents
(Cordis), 3.0–23 and 2.75–33 mm, were
deployed over the antegrade wire. Panel E
was the final angiograph. Finally, there were
no visible collateral flows from the left
coronary artery to d-RCA (panel F). The
patient has remained asymptomatic for
3 months after angioplasty.
Successful intervention of chronic total
occlusions has been reported to be associated
with a favourable long-term outcome and may reduce the need for bypass surgery. If previous
attempts to cross the totally occluded lesion from the anterograde approach fail, the retrograde
approach from collaterals should be considered. This technique cannot be applied in all cases of
chronic total occlusions, because it requires the presence of collaterals, but this method could be
another choice for solving a problem.
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